Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Blood (2012) 119 (5): 1123–1129.

https://doi.org/10.1182/blood-2011-08-376087

Published: 2012

Journal Articles

Impact of Dose Reductions and Interruptions Due to Adverse Events (AEs) on Efficacy in Newly Diagnosed Chronic Myeloid Leukemia in ChronicPhase (CML-CP) Patients (pts) Receiving Either Dasatinib (D) or Imatinib(IM): Analysis of the DASISION Trial

Elias Jabbour, Hagop M Kantarjian, Alfonso Quintas-Cardama, Francois Guilhot, MD, Chao Zhu, PhD, Janet Hong, PharmD, Zachary Cain, PharmD, Jorge E. Cortes

Blood (2011) 118 (21): 2768.

https://doi.org/10.1182/blood.V118.21.2768.2768

Published: 2011

Journal Articles

Dasatinib Compared with Imatinib In Newly Diagnosed Chronic Myelogenous Leukemia In Chronic Phase (CML-CP):Results of Japanese Subset Analysis In DASISION Trial.

Michinori Ogura, MD, PhD, Hirohisa Nakamae, MD, PhD, Shin Fujisawa, MD, PhD, Kenichi Ishizawa, MD, Masafumi Taniwaki, MD, PhD, Atae Utsunomiya, MD, PhD, Kosei Matsue, MD, PhD, Kazuo Tamura, MD, Kensuke Usuki, MD, PhD, Mitsune Tanimoto, MD, PhD, Yoji Ishida, MD, PhD, Hideki Akiyama, MD, PhD, Rika Sakai, MD, PhD, Masanobu Kasai, MD, PhD, Masayuki Hino, MD, PhD, Kyoji Ueda, MD, PhD, Taku Seriu, MD, PhD, M. Brigid Bradley-Garelik, MD, Chao Zhu, PhD

Blood (2010) 116 (21): 4484.

https://doi.org/10.1182/blood.V116.21.4484.4484

Published: 2010

Journal Articles

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up

Neil Shah, MD, Ph.D., Hagop Kantarjian, MD, Andreas Hochhaus, MD, Jorge E. Cortes, MD, M. Brigid Bradley-Garelik, MD, Chao Zhu, PhD, Michele Baccarani, MD

Blood (2010) 116 (21): 206.

https://doi.org/10.1182/blood.V116.21.206.206

Published: 2010

Journal Articles

Occurrence, Management, and Outcomes In Patients with Pleural Effusion During Dasatinib Treatment for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) In the First-Line Setting: Analysis of the DASISION Trial

Kimmo Porkka, MD, PhD, Michele Baccarani, MD, Andreas Hochhaus, MD, Hagop Kantarjian, MD, Satu Mustjoki, MD, PhD, M. Brigid Bradley-Garelik, MD, Chao Zhu, PhD, Jorge E. Cortes, MD

Blood (2010) 116 (21): 2282.

https://doi.org/10.1182/blood.V116.21.2282.2282

Published: 2010

Journal Articles

Predictors of Long-Term Cytogenetic Response Following Dasatinib Therapy of Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Elias Jabbour, Erkut Bahceci, Chao Zhu, Alexandre Lambert, Jorge Cortes

Blood (2009) 114 (22): 3296.

https://doi.org/10.1182/blood.V114.22.3296.3296

Published: 2009

Journal Articles

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Hagop Kantarjian, Jorge Cortes, Dong-Wook Kim, Pedro Dorlhiac-Llacer, Ricardo Pasquini, John DiPersio, Martin C. Müller, Jerald P. Radich, H. Jean Khoury, Nina Khoroshko, M. Brigid Bradley-Garelik, Chao Zhu, Martin S. Tallman

Blood (2009) 113 (25): 6322–6329.

https://doi.org/10.1182/blood-2008-11-186817

Published: 2009

Journal Articles

Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035

Richard A. Larson, MD, Oliver G. Ottmann, MD, Neil P. Shah, MD, PhD, Michael B. Lilly, MD, Josy M. Reiffers, Aude Charbonnier, Gerhard Ehninger, MD, M. Brigid Bradley-Garelik, Chao Zhu, Giovanni Martinelli, MD

Blood (2008) 112 (11): 2926.

https://doi.org/10.1182/blood.V112.11.2926.2926

Published: 2008

Journal Articles

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035

Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, PhD, Pedro Dorlhiac-Llacer, Ricardo Pasquini, Nina Khoroshko, John F. DiPersio, MD, PhD, Martin C Müller, MD, M. Brigid Bradley-Garelik, Chao Zhu, Martin S. Tallman, MD

Blood (2008) 112 (11): 3224.

https://doi.org/10.1182/blood.V112.11.3224.3224

Published: 2008

Journal Articles

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035

Giuseppe Saglio, MD, Hagop M. Kantarjian, MD, Andreas Hochhaus, MD, Yeow Tee Goh, MD, Tamas Masszi, MD, PhD, Ricardo Pasquini, Frederic Maloisel, M. Brigid Bradley-Garelik, Chao Zhu, Herve Dombret, MD, PhD, FRCP

Blood (2008) 112 (11): 3226.

https://doi.org/10.1182/blood.V112.11.3226.3226

Published: 2008

Journal Articles

Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015).

Kimmo Porkka, MD, Bengt Simonsson, MD, Herve Dombret, MD, Giovanni Martinelli, MD, Oliver G. Ottmann, MD, Chao Zhu, Jan M.A. Van Tornout, MD, Felix T. Garzon, MD, Richard A. Larson, MD

Blood (2007) 110 (11): 2810.

https://doi.org/10.1182/blood.V110.11.2810.2810

Published: 2007

Journal Articles

Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program.

Carlo Gambacorti, Jorge Cortes, Dong-Wook Kim, Herve Dombret, Chao Zhu, Jan M.A. Van Tornout, Felix T. Garzon, Michele Baccarani

Blood (2007) 110 (11): 472.

https://doi.org/10.1182/blood.V110.11.472.472

Published: 2007

NARROW

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Impact of Dose Reductions and Interruptions Due to Adverse Events (AEs) on Efficacy in Newly Diagnosed Chronic Myeloid Leukemia in ChronicPhase (CML-CP) Patients (pts) Receiving Either Dasatinib (D) or Imatinib(IM): Analysis of the DASISION Trial

Dasatinib Compared with Imatinib In Newly Diagnosed Chronic Myelogenous Leukemia In Chronic Phase (CML-CP):Results of Japanese Subset Analysis In DASISION Trial.

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up

Occurrence, Management, and Outcomes In Patients with Pleural Effusion During Dasatinib Treatment for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) In the First-Line Setting: Analysis of the DASISION Trial

Predictors of Long-Term Cytogenetic Response Following Dasatinib Therapy of Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035

Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015).

Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only